STOCK TITAN
  1. Home
  2. News
  3. TNDM

Tandem Diabetes Care Inc - TNDM STOCK NEWS

Welcome to our dedicated news page for Tandem Diabetes Care (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes Care.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tandem Diabetes Care's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tandem Diabetes Care's position in the market.

News
Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024
Rhea-AI Summary
Tandem Diabetes Care, Inc. (TNDM) is set to announce its first quarter 2024 results on May 2, 2024, followed by a conference call and webcast to discuss the financial and operating outcomes. Investors can access the live webcast on the company's Investor Center website and participate in the call using provided dial-in details. An archive of the webcast will be available for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
earnings
-
News
Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029
Rhea-AI Summary
Tandem Diabetes Care, Inc. (TNDM) announces the pricing of $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 in a private placement to qualified institutional buyers. The offering was upsized from $250.0 million, with an option for additional notes. The net proceeds are estimated to be around $266.3 million, to be used for various purposes including capped call transactions and repurchasing existing notes and common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
-
News
Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
Rhea-AI Summary
Tandem Diabetes Care, Inc. plans to offer $250.0 million of Convertible Senior Notes due 2029 in a private placement. The notes will be general unsecured obligations and will accrue interest semiannually. Tandem intends to use the net proceeds for capped call transactions, repurchasing existing notes, and buying back common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.96%
Tags
none
News
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance
Rhea-AI Summary
Tandem Diabetes Care, Inc. (TNDM) reports strong financial results for Q4 and FY 2023, with an increase in installed base, new product launches, and financial guidance for 2024. The company achieved positive momentum across key areas, including revenue growth, product launches, and operational improvement. The financial results show growth in sales, both in the US and internationally, with a focus on recurring revenue streams. Tandem aims to improve the lives of people with diabetes worldwide through its innovative products and platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.86%
Tags
earnings
-
News
Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System
Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) launches Tandem Mobi, the world's smallest durable automated insulin delivery system in the US. The Control-IQ technology predicts and prevents high and low blood sugar, improving time in range. The system is impressively small, wearable, and compatible with various infusion sets and sensors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
none
-
News
Tandem Diabetes Care Announces Upcoming Conference Presentations
Rhea-AI Summary
Tandem Diabetes Care, Inc. (TNDM) will present a company update at several investor conferences in February and March 2024. The presentations will be webcast live and accessible on the company's Investor Center website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
News
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) plans to release its Q4 and full year 2023 results on February 21, 2024, followed by a conference call and webcast to discuss the financial and operating results. The webcast will be available on Tandem Diabetes Care’s Investor Center website, and an archive will be accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
earnings
-
News
Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor
Rhea-AI Summary
Abbott (ABT) and Tandem Diabetes Care (TNDM) have announced the integration of the FreeStyle Libre 2 Plus sensor with the t:slim X2 insulin pump in the U.S. This marks the first time that Tandem's Control-IQ technology is compatible with the 15-day continuous glucose monitoring (CGM) sensor, providing a hybrid closed-loop system for users in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
News
ACRO Announces 2024 Officers and New Members
Rhea-AI Summary
ACRO (Association of Clinical Research Organizations) announced the election of Peyton Howell, Chief Operating & Growth Officer at Parexel, as Chair of the association effective Jan. 1, 2024. Lisa Moneymaker, Chief Technology Officer & Chief Product Officer at Saama, was elected Vice Chair. Mike Crowley, Chief Administrative Officer & General Counsel at Parexel, was elected Secretary, and Ari Feldman, Senior Vice President, Global Compliance and Strategy at Medidata Solutions, was re-elected Treasurer. ACRO also welcomed Advarra and YPrime as its newest members, reflecting the association's continued evolution in representing CROs and clinical technology companies that support drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
none
News
Tandem Diabetes Care Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers
Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced the launch of Tandem Source, a diabetes management platform for insulin pump users and healthcare providers. This platform consolidates various features into one central location, providing comprehensive data reporting and easy access to therapy data, supply reordering, and pump software updates. The platform has received positive feedback from early adopters in the United States and is expected to be available internationally by 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
none
Stock TNDM logo
Tandem Diabetes Care Inc

Nasdaq:TNDM

TNDM Rankings

#1781 Ranked by Market Cap
#5092 Ranked by Stock Gains
N/A Ranked by Dividends

TNDM Stock Data

2.16B
59.86M
0.63%
110.34%
14.19%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
San Diego

About TNDM

tandem diabetes care, inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. the company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. tandem manufactures and sells the t:slim x2™ insulin pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® insulin pump, the first pump designed for people with greater insulin requirements. tandem is based in san diego, california. safety information please note that this account is not intended to be used for product support or medical advice. if you are having a medical emergency, please dial 911. if you are having an issue with one of our products and need immediate assistance, please call our 24 hour customer support team at 877-801-6901 and press 1 twice. tandem insulin pumps are intended for the subcutan